Exceptional Survival Data, Lower Costs Key To The Competitive Advantage Of DCVax® – Northwest Biotherapeutics’ Vaccine For Multiple Cancers

Posted By :
Comments : Off
Comprehensive report by recognized Pharma and Biotech Analyst Dr. Navid Malik cites “striking data on survival” and “batch manufacturing at low cost” as key elements in DCVax’s “competitive advantage” in the “personalized cancer vaccine revolution.” BETHESDA, MD, June 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed...
Read More